Health economic assessment of the ATAC trial comparing anastrozole versus tamoxifen in adjuvant treatment of postmenopausal hormone receptor positive early breast cancer

被引：3

作者：

Annemans, L

Moeremans, K

Lamarque, H

机构：

[1] State Univ Ghent, HEDM, Meise, Belgium

[2] Astrazeneca, Rueil Malmaison, France

来源：

VALUE IN HEALTH | 2003年 / 6卷 / 06期

关键词：

D O I：

10.1016/S1098-3015(10)61604-X

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：625 / 625

页数：1

共 50 条

[41] Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial
Fallowfield, L
Cella, D
Cuzick, L
Francis, S
Locker, G
Howell, A
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (21) : 4261 - 4271
[42] Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective
Karnon, Jonathan
Delea, Thomas
Barghout, Vicki
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2008, 9 (02): : 171 - 183
[43] Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective
Jonathan Karnon
Thomas Delea
Vicki Barghout
The European Journal of Health Economics, 2008, 9
[44] The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women.
Baum, M
BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 210 - 210
[45] The anastrozole, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial in post-menopausal women: Regional variation in knowledge of hormone receptor status prior to randomisation into the trial. The ATAC Trialists' Group.
Howell, A
ANNALS OF ONCOLOGY, 2000, 11 : 20 - 20
[46] Cost-utility analysis of anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer (EBC): a UK National Health Service (NHS) perspective. The ATAC Trialists' Group
Mansel, Robert E.
ANNALS OF ONCOLOGY, 2004, 15 : 65 - 65
[47] Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal hormone-receptor positive advanced breast cancer.
Sobocki, P.
Borgstrom, F.
Kasteng, F.
Paulsson, T.
Lidgren, M.
Henriksson, R.
Lundkvist, J.
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S230 - S230
[48] Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer - A stochastic economic evaluation
Karnon, J
Brown, J
PHARMACOECONOMICS, 2002, 20 (02) : 119 - 137
[49] Comparison of cost-effectiveness of aromatase inhibitors letrozole, anastrozole or exemestane versus tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: Canadian perspective
El Ouagari, K.
Kamon, J.
Kaura, S.
EJC SUPPLEMENTS, 2007, 5 (04): : 210 - 211
[50] Cost-effectiveness analysis of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer in the UK
Karnon, J
Delea, TE
Papo, NL
Barghout, V
Thomas, SK
Johnston, SR
VALUE IN HEALTH, 2005, 8 (06) : A43 - A43

← 1 2 3 4 5 →